| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
12-14-2012, 02:20 PM
|
#1 | |||
|
||||
|
Senior Member
|
Newly identified compound can thwart protein implicated in Parkinson’s disease
12 Dec 2012, Posted by Yevgeniy Grigoryev | Sergey Brin, the co-founder of Google, has an increased risk of developing Parkinson’s disease because he harbors a mutation in a protein called Leucine-rich repeat kinase 2, or LRRK2. The protein is viewed as a promising drug target to treat Parkinson’s, a progressive neurological disorder, but it’s not possible to track LRRK2 activity in the brain, making the search for targeted therapies against the disease challenging. In a new study, researchers now provide evidence for a way to measure LRRK2 activity—and a new compound that can block the damaging effects of the protein in rodent neurons... http://blogs.nature.com/spoonful/201...#wpn-more-4111
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| LRRK2 variant publication | Parkinson's Disease | |||
| How LRRK2 mutations may cause Parkinson's | Parkinson's Disease | |||
| LRRK2 gene with the G2019S mutation | Parkinson's Disease | |||
LRRK2 inhibitor discovered; animal testing to begin
Linear Mode
